Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Inflammatix, a South Bay diagnostic test maker, has raised $57 million in Series E financing. The funding is expected to help the company advance its efforts in developing diagnostic tests for infectious diseases, including sepsis. Sepsis is a leading cause of death within hospitals and the most costly diagnosis among Medicare patients. The investment was backed by Khosla Ventures, which has supported Inflammatix's vision to create better and earlier detection methods for infectious diseases. Key figures in this achievement include Tim Sweeney and Purvesh Khatri.
We backed @Inflammatix_Inc early for their bold vision to develop a better and earlier way to detect infectious disease and sepsis, the leading cause of death within hospitals and the most costly diagnosis among Medicare patients. Excited to see their progress!…
How a South Bay diagnostic test maker, with a fresh $57 million, could win big in the fight against deadly sepsis https://t.co/Zb432d21DU
Congratulations @purveshkhatri and @TimSweeney83 and @Inflammatix_Inc for raising $57 million Series E for infection disease diagnostic testing, designing from #opendata! WAY TO GO!! https://t.co/c30HN5bWpM
